Recidivrisiko og varighed af antikoagulerende behandling efter dyb venøs trombose og lungeemboli

Willemijn Comuth, Anna-Marie Bloch Münster, Thomas Kümler, Maja Hellfritzsch Poulsen, Sanne Bøjet Larsen, Morten Lock Hansen, Erik Lerkevang Grove

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

If anticoagulant therapy is stopped, the risk of recurrence after unprovoked venous thromboembolism is high. After anticoagulant treatment for at least three months, the indication for prolonging therapy should be decided after thorough evaluation of individual risk factors for recurrence and bleeding. Clinical parameters, imaging modalities and D-dimer levels can guide this decision. The lower risk of bleeding on non-vitamin K-antagonist oral anticoagulants compared to warfarin is expected to increase the number of patients on extended treatment, but costs and patients’ preferences should be considered.
OriginalsprogDansk
ArtikelnummerV05180345
TidsskriftUgeskrift for Laeger
Vol/bind181
Udgave nummer21
Antal sider5
ISSN0041-5782
StatusUdgivet - 11. feb. 2019

Fingeraftryk

Patient Preference
Warfarin

Citer dette

Comuth, W., Münster, A-M. B., Kümler, T., Poulsen, M. H., Larsen, S. B., Hansen, M. L., & Grove, E. L. (2019). Recidivrisiko og varighed af antikoagulerende behandling efter dyb venøs trombose og lungeemboli. Ugeskrift for Laeger, 181(21), [V05180345].
Comuth, Willemijn ; Münster, Anna-Marie Bloch ; Kümler, Thomas ; Poulsen, Maja Hellfritzsch ; Larsen, Sanne Bøjet ; Hansen, Morten Lock ; Grove, Erik Lerkevang. / Recidivrisiko og varighed af antikoagulerende behandling efter dyb venøs trombose og lungeemboli. I: Ugeskrift for Laeger. 2019 ; Bind 181, Nr. 21.
@article{d73a413c876048898cadd878a6487903,
title = "Recidivrisiko og varighed af antikoagulerende behandling efter dyb ven{\o}s trombose og lungeemboli",
abstract = "If anticoagulant therapy is stopped, the risk of recurrence after unprovoked venous thromboembolism is high. After anticoagulant treatment for at least three months, the indication for prolonging therapy should be decided after thorough evaluation of individual risk factors for recurrence and bleeding. Clinical parameters, imaging modalities and D-dimer levels can guide this decision. The lower risk of bleeding on non-vitamin K-antagonist oral anticoagulants compared to warfarin is expected to increase the number of patients on extended treatment, but costs and patients’ preferences should be considered.",
author = "Willemijn Comuth and M{\"u}nster, {Anna-Marie Bloch} and Thomas K{\"u}mler and Poulsen, {Maja Hellfritzsch} and Larsen, {Sanne B{\o}jet} and Hansen, {Morten Lock} and Grove, {Erik Lerkevang}",
year = "2019",
month = "2",
day = "11",
language = "Dansk",
volume = "181",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "21",

}

Comuth, W, Münster, A-MB, Kümler, T, Poulsen, MH, Larsen, SB, Hansen, ML & Grove, EL 2019, 'Recidivrisiko og varighed af antikoagulerende behandling efter dyb venøs trombose og lungeemboli', Ugeskrift for Laeger, bind 181, nr. 21, V05180345.

Recidivrisiko og varighed af antikoagulerende behandling efter dyb venøs trombose og lungeemboli. / Comuth, Willemijn; Münster, Anna-Marie Bloch; Kümler, Thomas; Poulsen, Maja Hellfritzsch; Larsen, Sanne Bøjet; Hansen, Morten Lock; Grove, Erik Lerkevang.

I: Ugeskrift for Laeger, Bind 181, Nr. 21, V05180345, 11.02.2019.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Recidivrisiko og varighed af antikoagulerende behandling efter dyb venøs trombose og lungeemboli

AU - Comuth, Willemijn

AU - Münster, Anna-Marie Bloch

AU - Kümler, Thomas

AU - Poulsen, Maja Hellfritzsch

AU - Larsen, Sanne Bøjet

AU - Hansen, Morten Lock

AU - Grove, Erik Lerkevang

PY - 2019/2/11

Y1 - 2019/2/11

N2 - If anticoagulant therapy is stopped, the risk of recurrence after unprovoked venous thromboembolism is high. After anticoagulant treatment for at least three months, the indication for prolonging therapy should be decided after thorough evaluation of individual risk factors for recurrence and bleeding. Clinical parameters, imaging modalities and D-dimer levels can guide this decision. The lower risk of bleeding on non-vitamin K-antagonist oral anticoagulants compared to warfarin is expected to increase the number of patients on extended treatment, but costs and patients’ preferences should be considered.

AB - If anticoagulant therapy is stopped, the risk of recurrence after unprovoked venous thromboembolism is high. After anticoagulant treatment for at least three months, the indication for prolonging therapy should be decided after thorough evaluation of individual risk factors for recurrence and bleeding. Clinical parameters, imaging modalities and D-dimer levels can guide this decision. The lower risk of bleeding on non-vitamin K-antagonist oral anticoagulants compared to warfarin is expected to increase the number of patients on extended treatment, but costs and patients’ preferences should be considered.

M3 - Tidsskriftartikel

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 21

M1 - V05180345

ER -